Retrophin Reports Third Quarter 2018 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/24/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Retrophin (RTRX) Misses Q3 EPS by 23c, Revenues Miss
November 1, 2018 4:55 PM EDTRetrophin (NASDAQ: RTRX) reported Q3 EPS of ($0.68), $0.23 worse than the analyst estimate of ($0.45). Revenue for the quarter came in at $40.71 million versus the consensus estimate of $44.36 million.
I am pleased with the continued advancement of our first-in-class fosmetpantotenate and sparsentan programs and look... More



